Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Research

A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions

Authors: Omer Raheem, Anna A Kulidjian, Christina Wu, Young B Jeong, Tomonori Yamaguchi, Kristen M Smith, Daniel Goff, Heather Leu, Sheldon R Morris, Nicholas A Cacalano, Koichi Masuda, Catriona HM Jamieson, Christopher J Kane, Christina AM Jamieson

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Prostate cancer metastasizes to bone in the majority of patients with advanced disease leading to painfully debilitating fractures, spinal compression and rapid decline. In addition, prostate cancer bone metastases often become resistant to standard therapies including androgen deprivation, radiation and chemotherapy. There are currently few models to elucidate mechanisms of interaction between the bone microenvironment and prostate cancer. It is, thus, essential to develop new patient-derived, orthotopic models. Here we report the development and characterization of PCSD1 (Prostate Cancer San Diego 1), a novel patient-derived intra-femoral xenograft model of prostate bone metastatic cancer that recapitulates mixed osteolytic and osteoblastic lesions.

Methods

A femoral bone metastasis of prostate cancer was removed during hemiarthroplasty and transplanted into Rag2 -/- ;γ c -/- mice either intra-femorally or sub-cutaneously. Xenograft tumors that developed were analyzed for prostate cancer biomarker expression using RT-PCR and immunohistochemistry. Osteoblastic, osteolytic and mixed lesion formation was measured using micro-computed tomography (microCT).

Results

PCSD1 cells isolated directly from the patient formed tumors in all mice that were transplanted intra-femorally or sub-cutaneously into Rag2 -/- ;γ c -/- mice. Xenograft tumors expressed human prostate specific antigen (PSA) in RT-PCR and immunohistochemical analyses. PCSD1 tumors also expressed AR, NKX3.1, Keratins 8 and 18, and AMACR. Histologic and microCT analyses revealed that intra-femoral PCSD1 xenograft tumors formed mixed osteolytic and osteoblastic lesions. PCSD1 tumors have been serially passaged in mice as xenografts intra-femorally or sub-cutaneously as well as grown in culture.

Conclusions

PCSD1 xenografts tumors were characterized as advanced, luminal epithelial prostate cancer from a bone metastasis using RT-PCR and immunohistochemical biomarker analyses. PCSD1 intra-femoral xenografts formed mixed osteoblastic/osteolytic lesions that closely resembled the bone lesions in the patient. PCSD1 is a new primary prostate cancer bone metastasis-derived xenograft model to study metastatic disease in the bone and to develop novel therapies for inhibiting prostate cancer growth in the bone-niche.
Appendix
Available only for authorised users
Literature
1.
Sturge J, Caley MP, Waxman J: Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol. 2011, 8: 357-68.PubMed
2.
Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, Siddiqui J, Han B, Cao X, Smith DC, Shah RB, Chinnaiyan AM, Pienta KJ: Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res. 2011, 17: 3924-32. 10.1158/1078-0432.CCR-10-3120.PubMedCentralCrossRefPubMed
3.
Koeneman KS, Yeung F, Chung LW: Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 1999, 39: 246-261. 10.1002/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U.CrossRefPubMed
4.
5.
Kim HS, Freedland SJ: Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr Opin Support Palliat Care. 2010, 4: 147-52. 10.1097/SPC.0b013e32833bd913.CrossRefPubMed
6.
Guise T: Examining the metastatic niche: targeting the microenvironment. Semin Oncol. 2010, 37 (Suppl 2): S2-14.CrossRefPubMed
7.
Suva LJ, Washam C, Nicholas RW, Griffin RJ: Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011, 7: 208-18. 10.1038/nrendo.2010.227.PubMedCentralCrossRefPubMed
8.
Wilson C, Coleman RE: Adjuvant therapy with bone-targeted agents. CurrOpinSupportPalliatCare. 2011, 5: 241-50.
9.
Body JJ: New developments for treatment and prevention of bone metastases. Curr Opin Oncol. 2011, 23: 338-42. 10.1097/CCO.0b013e328347918b.CrossRefPubMed
10.
Puhaindran ME, Farooki A, Steensma MR, Hameed M, Healey JH, Boland PJ: Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am. 2011, 93: 1235-42. 10.2106/JBJS.J.01199.CrossRefPubMed
11.
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh HJ: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Clin Oncol. 2011, 29: 1125-32. 10.1200/JCO.2010.31.3304.CrossRef
12.
13.
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011, 377: 813-22. 10.1016/S0140-6736(10)62344-6.PubMedCentralCrossRefPubMed
14.
Sartor O: Denosumab in bone-metastatic prostate cancer: known effects on skeletal-related events but unknown effects on quality of life. Asian J Androl. 2011, 13: 612-3. 10.1038/aja.2011.33.PubMedCentralCrossRefPubMed
15.
Sonpavde G, Sternberg CN: Contemporary management of metastatic castration-resistant prostate cancer. Curr Opin Urol. 2011, 21: 241-7. 10.1097/MOU.0b013e3283449e19.CrossRefPubMed
16.
Smith MR, Brown GA, Saad F: New opportunities in the management of prostate cancer-related bone complications. Urologic Oncology: Seminars and Original Investigations. 2009, 27 (Suppl 1): S1-S20.CrossRef
17.
Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED: The TRAMP mouse as a model for prostate cancer. Current Protocols in Immunology. 2001, 20.5.1-20.5.23.
18.
Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL: The current state of preclinical prostate cancer animal models. Prostate. 2008, 68: 629-39. 10.1002/pros.20726.PubMedCentralCrossRefPubMed
19.
20.
Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL: Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate. 2002, 52: 20-33. 10.1002/pros.10091.CrossRefPubMed
21.
Davies MR, Lee YP, Lee C, Zhang X, Afar DE, Lieberman JR: Use of a SCID mouse model to select for a more aggressive strain of prostate cancer. Anticancer Res. 2003, 23: 2245-52.PubMed
22.
Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET: Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate. 2001, 47: 212-221. 10.1002/pros.1065.CrossRefPubMed
23.
Morrissey C, Kostenuik PL, Brown LG, Vessella RL, Corey E: Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases. BMC Cancer. 2007, 7: 148-10.1186/1471-2407-7-148.PubMedCentralCrossRefPubMed
24.
Tsingotjidou AS, Zotalis G: Development of an animal model for prostate cancer cell metastasis to adult human bone. Anticancer Res. 2001, 21: 971-8.PubMed
25.
Lee Y, Schwarz E, Davies M, Jo M, Gates J, Wu J, Zhang X, Lieberman JR: Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res. 2003, 21: 62-72. 10.1016/S0736-0266(02)00095-5.CrossRefPubMed
26.
Craft N, Chor C: Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Research. 1999, 59: 5030-5036.PubMed
27.
Gamradt SC, Feeley BT, Liu NQ, Roostaeian J, Lin YQ, Zhu LX, Sharma S, Dubinett SM, Lieberman JR: The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone. Anticancer Res. 2005, 25: 107-15.PubMed
28.
Feeley B, Gamradt SC, Hsu WK: Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone and Mineral Research. 2005, 20: 2189-2199. 10.1359/JBMR.050802.CrossRef
29.
Ristevski B, Jenkinson RJ, Stephen DJ, Finkelstein J, Schemitsch EH, McKee MD, Kreder HJ: Mortality and complications following stabilization of femoral metastatic lesions: a population-based study of regional variation and outcome. Can J Surg. 2009, 52: 302-308.PubMedCentralPubMed
30.
Piccioli A, Maccauro G, Rossi B, Scaramuzzo L, Frenos F, Capanna R: Surgical treatment of pathologic fractures of humerus. Injury. 2010, 41: 1112-6. 10.1016/j.injury.2010.08.015.CrossRefPubMed
31.
Hsu WK, Virk MS, Feeley BT, Stout DB, Chatziioannou AF, Lieberman JR: Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT. J Nucl Med. 2008, 49: 414-21. 10.2967/jnumed.107.045666.PubMedCentralCrossRefPubMed
32.
Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK: A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. CancerRes. 2009, 69: 1685-92.
33.
Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL: Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med. 1997, 3: 402-408. 10.1038/nm0497-402.CrossRefPubMed
34.
Nickerson T, Chang F, Lorimer D: In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 2001, 61: 6276-80.PubMed
35.
Sandberg R, Ernberg I: The molecular portrait of in vitro growth by meta-analysis of gene-expression profiles. Genome Biol. 2005, 6: R65-10.1186/gb-2005-6-8-r65.PubMedCentralCrossRefPubMed
36.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL: Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010, 18: 11-22. 10.1016/j.ccr.2010.05.026.PubMedCentralCrossRefPubMed
37.
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA: The genomic complexity of primary human prostate cancer. Nature. 2011, 470: 214-20. 10.1038/nature09744.PubMedCentralCrossRefPubMed
38.
Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, Huang C, Shankar S, Jing X, Iyer M, Hu M, Sam L, Grasso C, Maher CA, Palanisamy N, Mehra R, Kominsky HD, Siddiqui J, Yu J, Qin ZS, Chinnaiyan AM: Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res. 2011, 21: 1028-41. 10.1101/gr.119347.110.PubMedCentralCrossRefPubMed
39.
Virk MS, Petrigliano FA, Liu NQ, Chatziioannou AF, Stout D, Kang CO, Dougall WC, Lieberman JR: Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone. 2009, 44: 160-7. 10.1016/j.bone.2008.09.009.PubMedCentralCrossRefPubMed
40.
Hung TT, Chan J, Russell PJ, Power CA: Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. PLoS One. 2011, 6: e19389-10.1371/journal.pone.0019389.PubMedCentralCrossRefPubMed
41.
Bruni-Cardoso A, Johnson LC, Vessella RL, Peterson TE, Lynch CC: Osteoclast-Derived Matrix Metalloproteinase-9 Directly Affects Angiogenesis in the Prostate Tumor-Bone Microenvironment. Mol Cancer Res. 2010, 8: 459-70. 10.1158/1541-7786.MCR-09-0445.PubMedCentralCrossRefPubMed
42.
Chen CD, Welsbie DS, Tran C: Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004, 10: 33-39. 10.1038/nm972.CrossRefPubMed
43.
Collins AT, Berry PA, Hyde C: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65: 10946-10951. 10.1158/0008-5472.CAN-05-2018.CrossRefPubMed
44.
Duhagon MA, Hurte EM, Sotelo-Silveira JR, Zhang X, Farrar WL: Genomic profiling of tumor initiating prostatospheres. BMC Genomics. 2010, 11: 324-10.1186/1471-2164-11-324.PubMedCentralCrossRefPubMed
45.
Garraway IP, Sun W, Tran CP: Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate. 2010, 70: 491-501.PubMedCentralPubMed
46.
Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON: Identification of a cell of origin for human prostate cancer. Science. 2010, 329: 568-71. 10.1126/science.1189992.PubMedCentralCrossRefPubMed
47.
Gregg JL, Brown KE, Mintz EM: Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection. BMC Cancer. 2010, 10: 165-10.1186/1471-2407-10-165.PubMedCentralCrossRefPubMed
48.
Mitra N, Banda K, Altheide TK, Schaffer L, Johnson-Pais TL, Beuten J, Leach RJ, Angata T, Varki N, Varki A: SIGLEC12, a Human-specific Segregating (Pseudo)gene, Encodes a Signaling Molecule Expressed in Prostate Carcinomas. J Biol Chem. 2011, 286: 23003-11. 10.1074/jbc.M111.244152.PubMedCentralCrossRefPubMed
49.
Lavoie : Skin-derived precursors differentiate into skeletogenic cell types and contribute to bone repair. Stem Cells and Development. 2009, 18: 893-906. 10.1089/scd.2008.0260.CrossRefPubMed
50.
Ritacco LE: Three-dimensional morphometric analysis of the distal femur: a validity method for allograft selection using a virtual bone bank. Stud Health Technol Inform. 2010, 160: 1287-90.PubMed
51.
Ochia RS: Three-dimensional in vivo measurement of lumbar spine segmental motion. Spine. 2006, 31: 2073-8. 10.1097/01.brs.0000231435.55842.9e.CrossRefPubMed
52.
Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M, Jones C, Zehnder JL, Keating A, Negrin RS, Weissman IL, Jamieson CH: Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA. 2009, 106: 3925-9. 10.1073/pnas.0900189106.PubMedCentralCrossRefPubMed
53.
Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR: Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010, 120: 2715-30. 10.1172/JCI41824.PubMedCentralCrossRefPubMed
54.
Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL: Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad SciUSA. 2010, 107: 16759-65. 10.1073/pnas.1012443107.CrossRef
55.
Lawson DA, Zong Y, Memarzadeh S, Xin L: Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad SciUSA. 2010, 107: 2610-5. 10.1073/pnas.0913873107.CrossRef
56.
Ouyang B, Leung YK, Wang V, Chung E, Levin L, Bracken B, Cheng L, Ho SM: α-Methylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues. Urology. 2011, 77: 249.e1-7. 10.1016/j.urology.2010.08.005.CrossRef
57.
Johnson MB, Kawasawa YI, Mason CE: Functional and evolutionary insights into human brain development through global transcriptome analysis. Neuron. 2009, 62: 494-509. 10.1016/j.neuron.2009.03.027.PubMedCentralCrossRefPubMed
58.
Nervina JM, Magyar CE, Pirih FQ, Tetradis S: PGC-1alpha is induced by parathyroid hormone and coactivates Nurr1-mediated promoter activity in osteoblasts. Bone. 2006, 39: 1018-25. 10.1016/j.bone.2006.04.023.CrossRefPubMed
59.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005, 310: 644-8. 10.1126/science.1117679.CrossRefPubMed
60.
Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D: Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer. 2010, 116: 1406-18. 10.1002/cncr.24896.CrossRefPubMed
61.
Grubb RL, Deng J, Pinto PA: Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res. 2009, 8: 3044-54. 10.1021/pr8009337.PubMedCentralCrossRefPubMed
62.
Ugolkov AV, Eisengart LJ, Luan C, Yang XJ: Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate. 2011, 71: 18-25. 10.1002/pros.21217.CrossRefPubMed
63.
Wang X, Kruithof-de Julio M, Economides KD: A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009, 461: 495-500. 10.1038/nature08361.PubMedCentralCrossRefPubMed
64.
Petrigliano FA, Virk MS, Liu N, Sugiyama O, Yu D, Lieberman JR: Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter. Prostate. 2009, 69: 1422-34. 10.1002/pros.20989.CrossRefPubMed
65.
Schayek H, Seti H, Greenberg NM, Sun S, Werner H, Plymate SR: Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells. Mol Cell Endocrinol. 2010, 323: 239-45. 10.1016/j.mce.2010.04.017.PubMedCentralCrossRefPubMed
66.
Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB, Farrar WL: Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis. 2009, 26: 433-46. 10.1007/s10585-009-9242-2.PubMedCentralCrossRefPubMed
67.
Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E: Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer. 2009, 101: 263-8. 10.1038/sj.bjc.6605178.PubMedCentralCrossRefPubMed
68.
Tang Y, Hamburger AW, Wang L: Androgen deprivation and stem cell markers in prostate cancers. Int J Clin Exp Pathol. 2009, 3: 128-38.PubMedCentralPubMed
69.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009, 324: 787-90. 10.1126/science.1168175.PubMedCentralCrossRefPubMed
70.
Scher HI, Beer TM, Higano CS: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010, 375: 1437-46. 10.1016/S0140-6736(10)60172-9.PubMedCentralCrossRefPubMed
71.
Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ: Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011, 17: 4854-61. 10.1158/1078-0432.CCR-11-0815.PubMedCentralCrossRefPubMed
72.
Metadata
Title
A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions
Authors
Omer Raheem
Anna A Kulidjian
Christina Wu
Young B Jeong
Tomonori Yamaguchi
Kristen M Smith
Daniel Goff
Heather Leu
Sheldon R Morris
Nicholas A Cacalano
Koichi Masuda
Catriona HM Jamieson
Christopher J Kane
Christina AM Jamieson
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-185

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue

Research

An intronic SNP in the thyroid hormone receptor β gene is associated with pituitary cell-specific over-expression of a mutant thyroid hormone receptor β2 (R338W) in the index case of pituitary-selective resistance to thyroid hormone

Research

Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studies

Research

Fuzzy obesity index (MAFOI) for obesity evaluation and bariatric surgery indication

Research

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients

Research

Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning

Research

Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits